Purdue Pharma, the manufacturer of OxyContin, was sentenced in federal court on April 28, 2026, and ordered to pay $5.5 billion for its role in fueling the opioid epidemic [1]. This sentencing follows Purdue's 2020 guilty plea to charges of deceiving federal regulators and paying doctors to boost opioid sales [1]. Court documents revealed that Purdue illegally marketed its opioid products, defrauded the DEA by misrepresenting the effectiveness of its programs, and paid kickbacks to doctors through its speaker program [1].
The court ordered Purdue to pay a criminal fine of $3.544 billion, which will be assessed in connection with bankruptcy proceedings, and an additional $2 billion in criminal forfeiture, according to the Department of Justice [1]. Acting Attorney General Todd Blanche stated, "Purdue Pharma put profits over patient health and safety," emphasizing the company's willful disregard for the law and the resulting devastation caused by the opioid crisis [1]. FBI Director Kash Patel also condemned Purdue's actions, highlighting the company's role in the national epidemic and affirming the commitment of law enforcement to hold such companies accountable [1].
U.S. District Judge Madeline Cox Arleo presided over the sentencing, ordering Purdue Chairman Steve Miller to apologize directly to victims present in the courtroom. Nearly seven hours of victim testimony were heard, detailing the impact of Purdue's actions [1]. Miller expressed deep regret and accepted responsibility on behalf of the company [1]. Judge Arleo also criticized authorities for repeatedly failing to rein in Purdue, stating, "Your government failed you," and acknowledging the limitations of the legal remedies available [1].
Purdue Pharma, which was already preparing to pay $7.4 billion as part of a bankruptcy deal, announced that it will cease operations on May 1, 2026, following the court's sentence [1]. The company stated it is operating as usual until that date [1].
CONCLUSION
Purdue Pharma has been sentenced to pay $5.5 billion in criminal penalties for its role in the opioid epidemic and will cease operations by May 1, 2026. The case underscores the significant legal and financial consequences for companies involved in the opioid crisis, with authorities emphasizing accountability and victim impact.